May 17, 2022
STAMFORD, Conn. , May 17, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner , President and Chief
Additional Formats
May 09, 2022
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin)   approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients,
Additional Formats
May 03, 2022
STAMFORD, Conn. , May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner , President and Chief
Additional Formats
Apr 04, 2022
Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis STAMFORD, Conn. , April 04, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:
Additional Formats
Mar 28, 2022
Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting STAMFORD, Conn. , March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the
Additional Formats
Mar 08, 2022
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney
Additional Formats
Displaying 1 - 10 of 15
email alerts